Abstract:Ras proteins are membrane-associated, small guanine nucleotide-binding GTPases that control cell survival and proliferation. They consist of highly homologous catalytic domains and flexible C-terminal hypervariable regions (HVRs) that differ significantly across Ras isoforms, H-Ras, N-Ras, K-Ras4A and K-Ras4B, where KRas4B is among the frequently mutated oncogenes in human tumors. Recent NMR experiments discovered that the HVR of GDP-bound K-Ras4B extensively interacts with the catalytic domain. However, the HVR weakly interacts with the catalytic domain when the protein is in the GTP-bound state. Molecular dynamics (MD) simulations confirmed tight interaction of HVR with catalytic domain in the GDP-bound state, but not GTP-bound K-Ras4B, suggesting that in the GDP-bound state, an HVR domain could adopt a β-strand conformation, extending the β-sheet in the active site of the catalytic domain. Here we modeled K-Ras4B membrane interaction and dimerization. Membrane binding of K-Ras4B through the anchoring of the positively charged HVR is critical to its function as an oncogene and initiates signaling events. Recent studies showed that post-translationally modified HVR peptide spontaneously inserts the farnesyl group into the zwitterionic (DOPC) and anionic (DOPC:DOPS=4:1) bilayers in the liquid phase, but not into the DPPC bilayer in the gel phase. Further, spontaneous membrane insertion of the farnesyl group in full-length K-Ras4B strongly depends on the nucleotide type. The HVR of K-Ras4B-GTP preferentially interacts with lipids through the farnesyl insertion, while the HVR of K-Ras4B-GDP rather binds the catalytic domain and inserts less frequently the farnesyl into the lipid bilayer. Remarkably, K-Ras4B-GTP, but not GDP-bound, is able to form stable homodimers with different dimer interfaces, suggesting that the nucleotide-dependent dimerization with various dimer interfaces can resolve nanoclustering and cluster reorganization accomplishment with Raf's activation. Funded by Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E.

Bifunctional Small Molecule Ligands of K-Ras Induce Its Association with Immunophilin Proteins

K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function

design of Ras isoform selective binders

Drugging Ras Gtpase: A Comprehensive Mechanistic And Signaling Structural View

Drugging Ras GTPase: a Comprehensive Mechanistic and Signaling Structural View.

The structural basis for Ras activation of PI3Kα lipid kinase

Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity Measurements

GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

Design, Synthesis, and Biological Evaluation of New B-RafV600E Kinase Inhibitors

Reversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.

A Novel Strategy for Identifying Non-covalent KRas Inhibitors

RAS-inhibiting Biologics Identify and Probe Druggable Pockets Including an SII-α3 Allosteric Site

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway

Inhibition of K-Ras4B-plasma Membrane Association with a Membrane Microdomain-Targeting Peptide

Drugging K-RasG12C through covalent inhibitors: Mission possible?

Inhibitors of Ras–SOS Interactions

Nucleotide-Dependent Membrane Interaction and Dimerization of K-Ras4B

In Silico Identification of Novel Kinase Inhibitors by Targeting B-Rafv660e from Natural Products Database

Biophysical and Biochemical Characterization of Structurally Diverse Small Molecules Hits for KRAS Inhibition

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions